OBJECTIVE
This article describes pharmacology, pharmacokinetics, safety, and efficacy data of enlicitide, the first Food and Drug Administration (FDA)-approved oral proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i).
DATA SOURCES
PubMed, Embase, Web of Science, and Cochrane were searched through July 17...
Rachel C. Lucas, M. Lussier, Azadeh Nasuhidehnavi et al.· The Annals of Pharmacotherap...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.